Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000790793 | SCV000229767 | pathogenic | not provided | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000177827 | SCV000799244 | likely pathogenic | Merosin deficient congenital muscular dystrophy | 2018-04-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003736570 | SCV004540441 | pathogenic | LAMA2-related muscular dystrophy | 2023-09-28 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 92964). This premature translational stop signal has been observed in individual(s) with congenital muscular dystrophy (PMID: 30055037). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Glu1684*) in the LAMA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in LAMA2 are known to be pathogenic (PMID: 18700894, 32904964). |